Navigation Links
New agent strikes at respiratory syncytial virus replication
Date:5/5/2008

GALVESTON, Texas University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

In an effort to find an effective antiviral therapy for RSV, the scientists tested two types of complex, custom-designed molecule to interfere with the genetic machinery that RSV uses to replicate, or copy itself, within cells. Both of the so-called morpholino oligomers, created by Oregon-based AVI BioPharma, penetrated cultured human airway cells easily and produced only minimal toxicity. One of the two, designated AUG-2, significantly reduced RSV replication in both cell culture and mouse experiments.

Viral replication is one of the major pathogenetic processes of RSV, and we badly need a specific antiviral therapy, said UTMB Dr. Roberto Garofalo, senior author of a paper on the study to be published in the June issue of Molecular Therapy and now available in the Advance Online Publication section of the journals website. That's what an agent like this morpholino could give us.

RSV infects almost all children by age two, but normally causes only a cold-like upper respiratory infection. In some babies, however, it spreads to the lungs, where the inflammation it generates causes coughing, wheezing and extreme difficulty in breathing, a life-threatening clinical syndrome known as bronchiolitis.

Recent research by Garofalo and other investigators suggests that two key factors drive RSV bronchiolitis: an inflammatory overreaction by the cells that line the airways of the lungs, and a failure to respond to RSV by T lymphocytes (also known as T cells), immune system cells that ordinarily act to control viral infections.

Because a dangerous inflammatory response occurs so soon after RSV begins replicating in the lungs, Garofalo said, antiviral therapy by itself is unlikely to be sufficient to treat severe RSV infection in infants. But it could be a critical part of a combination therapy that also included drugs to reduce RSV-induced lung inflammation and boost T-cell response.

The virus continues to replicate for days in the lungs of infected infants, and it induces inflammation as long as it replicates, Garofalo said. So stopping viral replication would be a very important part of any therapeutic strategy for RSV.


'/>"/>
Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
2. China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
5. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
6. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. IUPUI scientists report first 3-D view of anti-cancer agent
10. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
11. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing broad access to life-saving drugs and ... is a better way to address this problem. , That was the message from ... and Economics at the University of Southern California, who served as the keynote speaker ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular perception, ... is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues ... violence in the United States. The study, Trends in Fighting and Violence ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... Colo. (PRWEB) , ... April 21, 2017 , ... The ... the Flex House, the next project in the company’s esteemed VISION House demonstration project ... homeowners use exactly the amount of resources they need to live affordably and abundantly ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
Breaking Medicine Technology: